InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.370 0.005 (1.37%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$113 Appendix 4G 27 Sep 2019 4:29PM $0.330 $0.370 risen by 12.12%
$113 2019 Annual Report 27 Sep 2019 4:24PM $0.330 $0.370 risen by 12.12%
$113 Key Family 2 Patent Granted in Japan for RECCE Antibiotics 20 Sep 2019 9:38AM $0.280 $0.370 risen by 32.14%
$113 R&D Incentive Rebate Received 18 Sep 2019 9:07AM $0.230 $0.370 risen by 60.87%
$113 Funding Update 11 Sep 2019 5:46PM $0.210 $0.370 risen by 76.19%
$113 Investor Presentation - September 2019 10 Sep 2019 9:58AM $0.215 $0.370 risen by 72.09%
$113 Appendix 4E - Preliminary Final Report 30 Aug 2019 4:39PM $0.230 $0.370 risen by 60.87%
$113 Notice of General Meeting/Proxy Form 30 Aug 2019 4:35PM $0.230 $0.370 risen by 60.87%
$113 Government Grant for University and Industry Collaboration 30 Aug 2019 11:11AM $0.225 $0.370 risen by 64.44%
$113 FDA Positive Response for Recce Scaled Manufacture & Quality 26 Aug 2019 10:15AM $0.215 $0.370 risen by 72.09%
$113 Response to ASX Appendix 4C Query 16 Aug 2019 5:09PM $0.215 $0.370 risen by 72.09%
$113 Change of Director's Interest Notice 14 Aug 2019 5:53PM $0.225 $0.370 risen by 64.44%
$113 Change of Director's Interest Notice 8 Aug 2019 5:09PM $0.220 $0.370 risen by 68.18%
$113 Key Family 2 Patent Granted in Europe for RECCE Antibiotics 8 Aug 2019 12:51PM $0.215 $0.370 risen by 72.09%
$113 Opening R&D Address at World Antibiotic Resistance Congress 1 Aug 2019 9:08AM $0.210 $0.370 risen by 76.19%
$113 Appendix 4C and commentary 30 Jul 2019 9:58AM $0.220 $0.370 risen by 68.18%
$113 R&D Incentive Rebate Received 30 Jul 2019 9:53AM $0.220 $0.370 risen by 68.18%
$113 Initial Director's Interest Notice 12 Jul 2019 4:40PM $0.220 $0.370 risen by 68.18%
$113 Appointment of Independent Chair and Additional Director 9 Jul 2019 10:31AM $0.230 $0.370 risen by 60.87%
$113 Leading Physician to Chair Clinical Advisory Committee 3 Jun 2019 9:14AM $0.210 $0.370 risen by 76.19%
$113 R&D Incentive Rebate Received 1 May 2019 11:34AM $0.230 $0.370 risen by 60.87%
$113 Appendix 4C and commentary 29 Apr 2019 9:26AM $0.255 $0.370 risen by 45.10%
$113 Investor Presentation - April 2019 10 Apr 2019 10:53AM $0.220 $0.370 risen by 68.18%
$113 USA Patent Granted for Recce's Antibiotics 14 Mar 2019 10:26AM $0.160 $0.370 risen by 131.25%
$113 Change of Director's Interest Notice 7 Mar 2019 8:29AM $0.150 $0.370 risen by 146.67%

501 - 525 of 725 results

Page 21 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.